Abstract
The treatment of chronic periodontitis is based on a comprehensive approach that includes supportive therapy, which requires patient commitment to treatment. Patient commitment to treatment is enhanced by the use of appropriate therapeutic regimens and the use of medications in the form of fixed combinations.
 Objective of the study: to assess the clinical effectiveness of a new pharmacological composition for the treatment of chronic periodontitis in patients with insufficient treatment adherence. 
 Materials and methods: a study and treatment were conducted on 92 patients with moderate-severity chronic periodontitis with insufficient treatment adherence (control group, n = 62 – received standard treatment; main group, n = 30 – received standard treatment supplemented with the new pharmacological composition). The level of treatment adherence was determined using the Treatment Adherence Quantification Questionnaire. Comparative assessment of treatment effectiveness in the study groups was conducted dynamically at control points (7, 14 days, 1, 6 months) based on clinical-instrumental data, periodontal tissue condition index assessment (OHI-S, PMA, PI), microcirculation condition (linear and volumetric blood flow velocities, pulsatility index). Disease outcome was recorded after 6 months: compensation, stabilization, or development of a new disease related to the primary one. 
 Results: The main group of patients showed statistically significantly lower PMA and PI index values at all control points. Microcirculation indicators significantly improved at the 14-day, 1-month, and 6-month control points compared to the control group. The recurrence rate after 6 months in the main group was 1.6 times lower than in the control group.
 Conclusion: The use of a new pharmacological composition for the treatment of chronic periodontitis in patients with insufficient treatment adherence showed clinical effectiveness, leading to longer stabilization of the process and compensation of the condition in over half of the cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.